Pro Medicus Limited develops and supplies healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe.
No risks detected for PME from our risk checks.
Share Price & News
How has Pro Medicus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PME is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: PME's weekly volatility (7%) has been stable over the past year.
7 Day Return
AU Healthcare Services
1 Year Return
AU Healthcare Services
Return vs Industry: PME exceeded the Australian Healthcare Services industry which returned 88.5% over the past year.
Return vs Market: PME exceeded the Australian Market which returned 28.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Pro Medicus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
12 hours ago | Simply Wall StPro Medicus Limited (ASX:PME) insiders sold AU$92m worth of stock suggesting impending weakness.
2 weeks ago | Simply Wall StPro Medicus' (ASX:PME) five-year total shareholder returns outpace the underlying earnings growth
1 month ago | Simply Wall StPro Medicus (ASX:PME) Knows How To Allocate Capital Effectively
Pro Medicus Fundamentals Summary
|PME fundamental statistics|
Is PME overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PME income statement (TTM)|
|Cost of Revenue||AU$490.00k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.30|
|Net Profit Margin||45.45%|
How did PME perform over the long term?See historical performance and comparison
0.3%Current Dividend Yield
Is Pro Medicus undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PME (A$59.03) is trading above our estimate of fair value (A$25.3)
Significantly Below Fair Value: PME is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PME is poor value based on its PE Ratio (199.7x) compared to the Global Healthcare Services industry average (57.4x).
PE vs Market: PME is poor value based on its PE Ratio (199.7x) compared to the Australian market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: PME is poor value based on its PEG Ratio (7.5x)
Price to Book Ratio
PB vs Industry: PME is overvalued based on its PB Ratio (75.4x) compared to the AU Healthcare Services industry average (4.4x).
How is Pro Medicus forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PME's forecast earnings growth (26.5% per year) is above the savings rate (1.9%).
Earnings vs Market: PME's earnings (26.5% per year) are forecast to grow faster than the Australian market (12% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PME's revenue (23.6% per year) is forecast to grow faster than the Australian market (5.9% per year).
High Growth Revenue: PME's revenue (23.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PME's Return on Equity is forecast to be very high in 3 years time (47.4%).
How has Pro Medicus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PME has high quality earnings.
Growing Profit Margin: PME's current net profit margins (45.4%) are higher than last year (40.6%).
Past Earnings Growth Analysis
Earnings Trend: PME's earnings have grown significantly by 30.3% per year over the past 5 years.
Accelerating Growth: PME's earnings growth over the past year (33.7%) exceeds its 5-year average (30.3% per year).
Earnings vs Industry: PME earnings growth over the past year (33.7%) underperformed the Healthcare Services industry 35.8%.
Return on Equity
High ROE: PME's Return on Equity (37.8%) is considered high.
How is Pro Medicus's financial position?
Financial Position Analysis
Short Term Liabilities: PME's short term assets (A$87.6M) exceed its short term liabilities (A$17.6M).
Long Term Liabilities: PME's short term assets (A$87.6M) exceed its long term liabilities (A$26.3M).
Debt to Equity History and Analysis
Debt Level: PME is debt free.
Reducing Debt: PME has not had any debt for past 5 years.
Debt Coverage: PME has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: PME has no debt, therefore coverage of interest payments is not a concern.
What is Pro Medicus's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PME's dividend (0.27%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.3%).
High Dividend: PME's dividend (0.27%) is low compared to the top 25% of dividend payers in the Australian market (5.39%).
Stability and Growth of Payments
Stable Dividend: PME is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: PME is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: PME is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PME's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Sam Aaron Hupert, M.B.B.S., MD has been the Chief Executive Officer and Managing Director at Pro Medicus Limited (alternate name: PRO Medicus Ltd.) since October 2010. Dr. Hupert serves as Member of Ad...
CEO Compensation Analysis
Compensation vs Market: Sam's total compensation ($USD369.39K) is below average for companies of similar size in the Australian market ($USD1.73M).
Compensation vs Earnings: Sam's compensation has been consistent with company performance over the past year.
Experienced Management: PME's management team is seasoned and experienced (10 years average tenure).
Experienced Board: PME's board of directors are considered experienced (8.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pro Medicus Limited's company bio, employee growth, exchange listings and data sources
- Name: Pro Medicus Limited
- Ticker: PME
- Exchange: ASX
- Founded: 1983
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$6.239b
- Shares outstanding: 104.39m
- Website: https://www.promed.com.au
- Pro Medicus Limited
- 450 Swan Street
Pro Medicus Limited develops and supplies healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. It pro...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 08:06|
|End of Day Share Price||2021/09/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.